JO
VTGN icon

John Overdeck’s VistaGen Therapeutics VTGN Stock Holding History

John Overdeck’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192K Buy
847,992
+378,373
+81% +$228K ﹤0.01% 4797
2026
Q1 		$268K Buy
469,619
+274,049
+140% +$167K ﹤0.01% 4139
2025
Q4 		$129K Sell
195,570
-93,839
-32% -$339K ﹤0.01% 3833
2025
Q3 		$1.03M Buy
289,409
+199,958
+224% +$597K ﹤0.01% 2556
2025
Q2 		$179K Sell
89,451
-23,056
-20% -$52.4K ﹤0.01% 2938
2025
Q1 		$281K Sell
112,507
-24,827
-18% -$70.3K ﹤0.01% 2741
2024
Q4 		$405K Buy
137,334
+75,792
+123% +$213K ﹤0.01% 2629
2024
Q3 		$185K Sell
61,542
-5,969
-9% -$20.4K ﹤0.01% 2812
2024
Q2 		$235K Sell
67,511
-76,875
-53% -$333K ﹤0.01% 2682
2024
Q1 		$762K Sell
144,386
-47,673
-25% -$229K ﹤0.01% 2123
2023
Q4 		$987K Buy
+192,059
New +$727K ﹤0.01% 2088
2023
Q2 		– Sell
-11,043
Closed -$41.3K – 3283
2023
Q1 		$41.3K Sell
11,043
-10,990
-50% -$57.6K ﹤0.01% 2781
2022
Q4 		$68.1K Sell
22,033
-6,170
-22% -$23.2K ﹤0.01% 2559
2022
Q3 		$129K Buy
28,203
+26,425
+1,486% +$262K ﹤0.01% 2193
2022
Q2 		$47K Sell
1,778
-11,109
-86% -$392K ﹤0.01% 2353
2022
Q1 		$479K Sell
12,887
-2,837
-18% -$124K ﹤0.01% 2041
2021
Q4 		$920K Sell
15,724
-21,565
-58% -$1.4M ﹤0.01% 2633
2021
Q3 		$3.06M Sell
37,289
-2,348
-6% -$204K 0.01% 1597
2021
Q2 		$3.75M Buy
39,637
+8,372
+27% +$620K 0.01% 1380
2021
Q1 		$2M Buy
31,265
+26,548
+563% +$1.77M 0.01% 1710
2020
Q4 		$275K Buy
4,717
+4,080
+641% +$104K ﹤0.01% 2929
2020
Q3 		$13K Buy
+637
New +$13.2K ﹤0.01% 3007

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

John Overdeck's VTGN Position: Q2 2026 in Review

John Overdeck increased its VistaGen Therapeutics (VTGN) stake by 81% in Q2 2026, buying an estimated $228K and bringing the position to 847,992 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #4797.

John Overdeck first reported a position in VTGN in Q3 2020 and has held it in 22 quarters since. The position peaked at $3.75M in Q2 2021. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • John Overdeck held 847,992 shares of VistaGen Therapeutics worth $192K as of Q2 2026.
  • John Overdeck bought 378,373 VistaGen Therapeutics shares in Q2 2026, an estimated $228K.
  • VistaGen Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4797 holding.
  • John Overdeck first reported a position in VistaGen Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • John Overdeck's VistaGen Therapeutics position peaked at $3.75M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.